Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 3/2005

01-03-2005 | Editorial

New directions in supportive care

Author: Steven M. Grunberg

Published in: Supportive Care in Cancer | Issue 3/2005

Login to get access

Abstract

Supportive care has traditionally emphasized symptom management and subjective evaluation of quality of life. However, recent advances in molecular biology and molecular genetics are as exciting for supportive care as they are for cytotoxic therapy. Relevant receptor mutations may alter sensitivity to antiemetics or to analgesics while variations in metabolic pathways may affect either efficacy of supportive care agents or toxicity of the chemotherapeutic agents themselves. Altered ligands for various receptors can produce differential effects conducive to better symptom management. Even symptoms such as fatigue and overall outlook may be defined in terms of appropriate enzymatic pathways. Evaluation and application of these advances in basic science are leading directly to new directions in supportive care.
Literature
1.
Ahlberg K, Ekman T, Gaston-Johansson F (2004) Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: a pilot study. Biol Res Nurs 5:203–210CrossRefPubMed
2.
Barnes NM, Bunce KT, Naylor RJ, et al (1991) The actions of fentanyl to inhibit drug induced emesis. Neuropharmacology 30:1073–1083CrossRefPubMed
3.
Burstein SH (1999) The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 82:87–96CrossRefPubMed
4.
Innocenti F, Undevia SD, Iyer L, et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382–1388CrossRefPubMed
5.
Kaiser R, Sezer O, Papies A, et al (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805–2811CrossRefPubMed
6.
Kaiser R, Tremblay PB, Sezer O, et al (2004) Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics 14:271–278CrossRefPubMed
7.
Meropol NJ, Somer RA, Gutheil J, et al (2003) Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 21:1452–1458CrossRefPubMed
8.
Schuller AG, King MA, Zhang J, et al (1999) Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 2:151–156CrossRefPubMed
9.
Sloan JA, McLeod H, Sargent D, et al (2004) Preliminary evidence of relationship between genetic markers and oncology patient quality of life. J Clin Oncol [Suppl] 22:2
10.
Thomas J, Portenoy R, Moehl M, et al (2003) A phase II randomized dose-finding trial of methylnaltrexone for the relief of opioid-induced constipation in hospice patients. Proc ASCO 22:729
11.
Tremblay PB, Kaiser R, Sezer O, et al (2003) Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 21:2147–2155CrossRefPubMed
12.
Wratten C, Kilmurray J, Nash S, et al (2004) Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys 59:160–167CrossRefPubMed
Metadata
Title
New directions in supportive care
Author
Steven M. Grunberg
Publication date
01-03-2005
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 3/2005
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0742-y

Other articles of this Issue 3/2005

Supportive Care in Cancer 3/2005 Go to the issue

Short Communication

Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain

Review Article

Contribution to variability in response to opioids

Letter to the Editor

Letter to the Editor

Original Article

Successful use of ketamine for intractable cancer pain

Forthcoming Meetings

Forthcoming Meetings March 2005

Original Article

Nutritional status of cancer patients and its relationship to function in an inpatient rehabilitation setting
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits